MY157852A - A platform for transdermal formulations (ptf) - Google Patents

A platform for transdermal formulations (ptf)

Info

Publication number
MY157852A
MY157852A MYPI20032357A MYPI20032357A MY157852A MY 157852 A MY157852 A MY 157852A MY PI20032357 A MYPI20032357 A MY PI20032357A MY PI20032357 A MYPI20032357 A MY PI20032357A MY 157852 A MY157852 A MY 157852A
Authority
MY
Malaysia
Prior art keywords
platform
ptf
transdermal formulations
therapeutically active
transdermal
Prior art date
Application number
MYPI20032357A
Other languages
English (en)
Inventor
Yuval Simha Landschaft
Original Assignee
Holden Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Holden Dev Ltd filed Critical Holden Dev Ltd
Publication of MY157852A publication Critical patent/MY157852A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI20032357A 2002-06-27 2003-06-24 A platform for transdermal formulations (ptf) MY157852A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10228680A DE10228680A1 (de) 2002-06-27 2002-06-27 Grundlage für transdermale Formulierungen (PTF)

Publications (1)

Publication Number Publication Date
MY157852A true MY157852A (en) 2016-07-29

Family

ID=29761469

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20032357A MY157852A (en) 2002-06-27 2003-06-24 A platform for transdermal formulations (ptf)

Country Status (14)

Country Link
US (1) US20050118241A1 (enExample)
EP (1) EP1515706A2 (enExample)
JP (1) JP2005535635A (enExample)
KR (1) KR20050027995A (enExample)
CN (1) CN1665492A (enExample)
AR (1) AR040287A1 (enExample)
AU (1) AU2003252459A1 (enExample)
CA (1) CA2490022A1 (enExample)
DE (1) DE10228680A1 (enExample)
MX (1) MXPA04012732A (enExample)
MY (1) MY157852A (enExample)
TW (1) TW200500093A (enExample)
WO (1) WO2004002444A2 (enExample)
ZA (1) ZA200500710B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033998B2 (en) * 2003-04-11 2006-04-25 All Natural Fmg, Inc. Alcohol-free transdermal insulin composition and processes for manufacture and use thereof
US7396819B2 (en) * 2003-08-08 2008-07-08 Virbac Corporation Anthelmintic formulations
WO2005094210A2 (en) * 2004-03-12 2005-10-13 The Hartz Mountain Corporation Multi-action anthelmintic formulations
US10042980B2 (en) 2005-11-17 2018-08-07 Gearbox Llc Providing assistance related to health
US20110145009A1 (en) * 2005-11-30 2011-06-16 Jung Edward K Y Methods and systems related to transmission of nutraceutical associatd information
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US20120283332A1 (en) * 2009-05-12 2012-11-08 Ohio University Transdermal delivery of metformin
US10363229B2 (en) 2009-06-05 2019-07-30 Joan McInyre Caron Methods and compositions for the treatment of cancer
RU2659729C2 (ru) * 2012-07-30 2018-07-03 Матинас Биофарма Нанотекнолоджис, Инк. Кохлеаты, полученные с использованием фосфатидилсерина сои

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4878892A (en) * 1987-02-10 1989-11-07 Drug Delivery Systems Inc. Electrolytic transdermal delivery of polypeptides
FR2616333A1 (fr) * 1987-06-12 1988-12-16 Cird Procede d'ionophorese pour administrer une substance dissoute ou partiellement dissoute, par voie percutanee ou perungueale et dispositif correspondant
JPS63316737A (ja) * 1987-06-19 1988-12-26 Toyo Jozo Co Ltd 経鼻投与用医薬組成物
IT1223343B (it) * 1987-11-03 1990-09-19 Also Lab Sas Formulazioni farmaceutiche per somministrazione transdermica
US5332577A (en) * 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
EP0429842B1 (en) * 1989-10-27 1996-08-28 Korea Research Institute Of Chemical Technology Device for the transdermal administration of protein or peptide drug
US5073539A (en) * 1990-01-22 1991-12-17 Ciba-Geigy Corporation Transdermal administration of zwitterionic drugs
DE69216836T2 (de) * 1991-07-26 1997-06-12 Smithkline Beecham Corp W/o mikroemulsionen
FR2687321B1 (fr) * 1992-02-14 1999-04-16 Elf Aquitaine Dispositif d'ionophorese pour l'administration transcutanee d'une quantite totale donnee d'un principe actif a un sujet.
WO1996010439A1 (en) * 1994-09-30 1996-04-11 Kabushiki Kaisya Advance Interface for iontophoretic percutaneous administration, and agent and method for treating the skin for that purpose
US5707641A (en) * 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
US5759445A (en) * 1995-05-24 1998-06-02 Matsushita Electric Industrial Co., Ltd. Lipid-dispersed solution and process for producing the same
US6183758B1 (en) * 1998-01-29 2001-02-06 Highland Laboratories, Inc. Phytochemicals, nutrients & medication absorption &/or treatment
JP2002519366A (ja) * 1998-07-07 2002-07-02 トランスダーマル・テクノロジーズ・インコーポレーテツド 医薬的に活性な作用物質を迅速かつ非刺激的に経皮送達するための組成物、およびそのような組成物の調剤法およびそれらの送達
CA2369594A1 (en) * 1999-05-07 2000-11-16 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents

Also Published As

Publication number Publication date
WO2004002444A2 (en) 2004-01-08
CN1665492A (zh) 2005-09-07
TW200500093A (en) 2005-01-01
WO2004002444A3 (en) 2004-03-11
ZA200500710B (en) 2005-09-05
AR040287A1 (es) 2005-03-23
US20050118241A1 (en) 2005-06-02
CA2490022A1 (en) 2004-01-08
JP2005535635A (ja) 2005-11-24
MXPA04012732A (es) 2005-11-17
EP1515706A2 (en) 2005-03-23
AU2003252459A1 (en) 2004-01-19
DE10228680A1 (de) 2004-01-22
KR20050027995A (ko) 2005-03-21

Similar Documents

Publication Publication Date Title
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AP1954A (en) Controlled release compositions comprising nimesulide.
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
AU2274201A (en) Compounds and compositions for delivering active agents
TR200103493T2 (tr) Metaloproteaz önleyicileri
NZ524767A (en) Composition for the transdermal delivery of fentanyl
GB2388778B (en) Method and composition for combatting pesticide resistance
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
WO2003045306A3 (en) Phenoxy amine compounds and compositions for delivering active agents
WO2004058721A3 (en) Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity
WO2004093800A3 (en) Thyronamine derivatives and analogs and methods of use thereof
TW200500093A (en) A platform for transdermal formulations (PTF)
TW200509794A (en) Novel anthelmintic and insecticidal compositions
SE9800905L (sv) Ny terapi vid glomerulonefrit
DK1216043T3 (da) Formulering med forsinket frigivelse indeholdende alfa-liponsyre-(derivater)
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
AU2002241270A1 (en) Compositions for delivering biologically active drug and method of using the same
AU2003235931A1 (en) Vintoperol-containing medicinal composition for transdermal administration
MXPA05006378A (es) Compuestos esteroides con actividad anti-tumoral.
AU2001292423A1 (en) Formulations for reducing or eliminating toxicity of environmental hormones containing ursodeoxycholic acid
AU6629000A (en) Novel hypoxanthine and thiohypoxanthine compounds
MXPA04006269A (es) Composicion farmaceutica que comprende un inhibidor de alfa-glucosidasa y acido 4-oxobutanoico y uso de la misma para tratamiento de diabetes.